文献速递中医内科中药与中成药合理使用中医康复

参麦注射液治疗扩张型心肌病的疗效与安全性:随机对照试验的系统评价与Meta分析

Efficacy and safety evaluation of Shenmai injections for dilated cardiomyopathy: A systematic review and meta-analysis of randomised controlled trials.
PubMed 文献 · Phytomedicine · 2022-12-26

该系统评价纳入16项随机对照试验共1455例扩张型心肌病患者,评估参麦注射液联合常规治疗的疗效与安全性。Meta分析显示联合治疗可提高临床有效率、改善心功能指标且未观察到严重不良反应,但证据质量评级为极低至低,主要受方法学质量差、样本量小和异质性高限制。

要点

  • 参麦注射液联合常规治疗可能提高扩张型心肌病患者临床有效率(OR=3.65,95%CI 2.52-5.28)。
  • 联合治疗可改善LVEF、LVEDD、LVESD、BNP、NT-proBNP及6分钟步行距离等心功能指标。
  • 研究期间未观察到与参麦注射液相关的严重不良反应,但证据质量评级为极低至低。

核心结论

  • 参麦注射液联合常规治疗对扩张型心肌病患者改善心功能可能有益且安全性较好。
  • 由于纳入试验方法学质量低,需更多严格高质量随机对照试验提供坚实证据。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、EMBASE、Cochrane Library、SinoMed、万方、CNKI和VIP数据库至2022年7月1日。
  • 纳入16项随机对照试验,共1455例参与者,采用Cochrane工具评估偏倚风险,R软件分析,GRADE评级证据质量。

主要发现

  • 联合参麦注射液治疗显著提高临床有效率(OR=3.65,95%CI 2.52-5.28,p<0.01)。
  • 联合治疗提高左心室射血分数(MD=5.31,95%CI 4.21-6.40,p<0.01)。
  • 联合治疗降低左心室舒张末期内径(MD=-4.57,95%CI -7.10至-2.04,p<0.01)和收缩末期内径(MD=-2.46,95%CI -3.60至-1.33,p<0.01)。
  • 联合治疗降低脑钠肽(MD=-215.85,95%CI -241.61至-190.10,p<0.01)和N末端脑钠肽前体(MD=-504.42,95%CI -687.73至-321.10,p<0.01)。
  • 联合治疗增加6分钟步行距离(MD=114.08,95%CI 42.32-185.85,p<0.01),研究期间未观察到与参麦注射液相关的严重不良反应。

关键数值与推荐

  • 临床有效率OR=3.65(95%CI 2.52-5.28,p<0.01)。
  • LVEF MD=5.31(95%CI 4.21-6.40,p<0.01);LVEDD MD=-4.57(95%CI -7.10至-2.04,p<0.01);LVESD MD=-2.46(95%CI -3.60至-1.33,p<0.01)。
  • BNP MD=-215.85(95%CI -241.61至-190.10,p<0.01);NT-proBNP MD=-504.42(95%CI -687.73至-321.10,p<0.01);6MWD MD=114.08(95%CI 42.32-185.85,p<0.01)。
  • 证据质量评级为极低至低,主要因纳入随机对照试验方法学质量差、样本量小、异质性高和潜在发表偏倚。

临床怎么用

  • 在常规治疗基础上可考虑联合参麦注射液以改善扩张型心肌病患者心功能,但需结合证据质量极低至低谨慎决策。
  • 临床应用中应监测心功能指标和不良反应,并优先参考更高质量证据。

局限性

  • 纳入随机对照试验方法学质量差。
  • 样本量小且异质性高。
  • 存在潜在发表偏倚,证据质量评级为极低至低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shenmai Injection (SMI), a Chinese herbal injection, is widely used in China for the adjuvant treatment of patients with dilated cardiomyopathy (DCM), yet its clinical efficacy and safety remain controversial. PURPOSE: The aim of this study was to systematically evaluate the efficacy and safety of SMI in the treatment of DCM. METHODS: Randomised controlled trials (RCTs) of SMI in the treatment of DCM were searched for and collected from the PubMed, EMBASE, Cochrane Library, SinoMed, Wan Fang, CNKI, and VIP databases between the dates of establishment of each database and July 1, 2022. The methodological quality of the included studies was assessed, while the risk of bias was based on the Cochrane Collaboration tool. All data were analysed using the R software. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was applied to rate the quality of the evidence. RESULTS: In total, 16 RCTs, including 1,455 participants, were examined in this study. Evidence showed that the combination of SMI treatment and conventional treatment appears to significantly increase the clinical efficacy rate (OR=3.65, 95%CI (2.52, 5.28), p < 0.01), improve cardiac function (e.g. increase left ventricular ejection fraction (LVEF) (MD=5.31, 95%CI (4.21, 6.40), p < 0.01), decrease left ventricular end-diastolic dimension (LVEDD) (MD=-4.57, 95% CI (-7.10, -2.04); p < 0.01) and left ventricular end-systolic diameter (LVESD) (MD=-2.46, 95% CI (-3.60, -1.33); p < 0.01), decrease brain natriuretic peptide (BNP) (MD=-215.85, 95% CI (-241.61, -190.10); p < 0.01) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) (MD=-504.42, 95% CI (-687.73, -321.10); p < 0.01), and increase 6-min walk distance (6MWD) (MD=114.08, 95% CI (42.32, 185.85); p < 0.01).In addition, no serious adverse effects associated with SMI were observed during the study period, thus suggesting that SMI is safe. However, the quality of evidence for these results was rated as "very low" to "low", mainly due to the poor methodological quality of the included RCTs, the small sample size, the high heterogeneity, and potential publication bias. CONCLUSION: In the present work, we provide evidence that combined SMI therapy is beneficial and safe for improving cardiac function in patients with DCM. However, due to limitations posed by the low methodological quality of the included trials, more rigorous and high-quality RCTs are needed to provide solid evidence.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Wang Y, Liu Q, Kong Y, et al. Efficacy and safety evaluation of Shenmai injections for dilated cardiomyopathy: A systematic review and meta-analysis of randomised controlled trials. Phytomedicine. 2022. PMID: 36608499. doi:10.1016/j.phymed.2022.154630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。